Healthcare / Drug Manufacturers - Specialty & GenericBSE
$266.10
+3.95 (+1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $-127.3M · quality 19.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.3B
P/E
13.9x
↓EV/EBITDA
13.5x
↑ROE
51.5%
↑Gross Margin
51.4%
↑Debt/Equity
2.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.4%
FCF CAGR
—
FCF margin
-3.9%
FCF / Net income
-0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.94B · net income $305.3M · FCF $-229.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.94B | $5.94B | $5.74B | $4.98B | $5.07B |
| Net Income | $305.3M | $305.3M | $559.6M | $-104.0M | $814.7M |
| EBITDA | $798.1M | $798.1M | $985.5M | $234.9M | $1.13B |
| EPS | 8.98 | 8.98 | 16.89 | -3.18 | 25.21 |
| Gross Margin | 51.4% | 51.4% | 46.0% | 38.0% | 39.7% |
| Operating Margin | 10.6% | 10.6% | 10.0% | 2.4% | 5.7% |
| Net Margin | 5.1% | 5.1% | 9.7% | -2.1% | 16.1% |
| Balance Sheet | |||||
| Debt/Equity | 2.98 | 2.98 | 4.14 | -3.31 | -4.60 |
| Cash Flow | |||||
| Free Cash Flow | $-229.3M | $-229.3M | $-127.3M | $71.7M | $308.7M |
| Returns | |||||
| ROE | 51.5% | 51.5% | 200.3% | 31.7% | -347.9% |
| Valuation | |||||
| P/E | 13.91 | 13.91 | 9.85 | — | 3.36 |
| EV/EBITDA | 13.49 | 13.49 | 6.74 | 10.23 | 3.17 |
| P/B | 15.26 | 15.26 | 19.73 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 3.3% | 3.3% | 15.3% | -1.8% | — |
| EPS Growth | -46.8% | -46.8% | 631.1% | -112.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
38.0%
EPS terminal req.
$23.61
Spread vs growth
-84.9%
5Y implied EPS CAGR
26.0%
EPS terminal req.
$28.57
Spread vs growth
-72.9%
10Y implied EPS CAGR
17.7%
EPS terminal req.
$46.01
Spread vs growth
-64.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.1%
Start / end P/E
17.2x → 34.0x
EPS bridge
16.89 → 8.98
Residual
-45.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.